Clinical Trial Detail

NCT ID NCT04164901
Title Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

astrocytoma

oligodendroglioma

Therapies

AG-881

Age Groups: senior child adult

Additional content available in CKB BOOST